Ocular Pain - Pipeline Review, H1 2016
SKU ID :GMD-10114565 | Published Date: 22-Mar-2016 | No. of pages: 70Description
TOC
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ocular Pain Overview 7
Therapeutics Development 8
Pipeline Products for Ocular Pain - Overview 8
Ocular Pain - Therapeutics under Development by Companies 9
Ocular Pain - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Ocular Pain - Products under Development by Companies 13
Ocular Pain - Companies Involved in Therapeutics Development 14
InSite Vision Incorporated 14
Kala Pharmaceuticals, Inc. 15
Ocular Therapeutix, Inc. 16
Reata Pharmaceuticals, Inc. 17
Sylentis S.A.U. 18
Valeant Pharmaceuticals International, Inc. 19
Ocular Pain - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
(bromfenac sodium + dexamethasone acetate) - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dexamethasone acetate SR - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
difluprednate XR - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ISV-303 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ketorolac tromethamine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
loteprednol etabonate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
loteprednol etabonate next generation - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NT-71 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
NT-72 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
omaveloxolone - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
RX-10045 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Block NaV1.7 Channel for Pain and Pruritus - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SYL-1001 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Ocular Pain - Recent Pipeline Updates 48
Ocular Pain - Dormant Projects 61
Ocular Pain - Product Development Milestones 62
Featured News & Press Releases 62
Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome 62
Jan 11, 2016: Ocular Therapeutix Strengthens Executive Management Team with the Appointment of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., as Chief Medical Officer 62
Dec 09, 2015: Ocular Therapeutix Announces FDA Acceptance of NDA Filing for DEXTENZA for the Treatment of Post-Surgical Ocular Pain 63
Oct 14, 2015: Ocular Therapeutix Begins Enrollment in Third Phase 3 Clinical Trial for DEXTENZA for the Treatment of Post-Surgical Ocular Inflammation and Pain 64
Sep 02, 2015: InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit 64
Aug 17, 2015: InSite Vision Announces FDA Acceptance of NDA Filing for BromSite 65
May 15, 2015: Ocular Therapeutix Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication 65
Oct 01, 2013: Ocular Therapeutix Announces Phase 2 Study Results for Sustained Release Dexamethasone 67
Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 67
May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70
Tables & Figures
List of Tables
Number of Products under Development for Ocular Pain, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Ocular Pain - Pipeline by InSite Vision Incorporated, H1 2016 14
Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H1 2016 15
Ocular Pain - Pipeline by Ocular Therapeutix, Inc., H1 2016 16
Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 17
Ocular Pain - Pipeline by Sylentis S.A.U., H1 2016 18
Ocular Pain - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Assessment by Combination Products, H1 2016 21
Number of Products by Stage and Target, H1 2016 23
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Ocular Pain Therapeutics - Recent Pipeline Updates, H1 2016 48
Ocular Pain - Dormant Projects, H1 2016 61
List of Figures
Number of Products under Development for Ocular Pain, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Top 10 Targets, H1 2016 22
Number of Products by Stage and Top 10 Targets, H1 2016 22
Number of Products by Mechanism of Actions, H1 2016 24
Number of Products by Stage and Mechanism of Actions, H1 2016 24
Number of Products by Routes of Administration, H1 2016 26
Number of Products by Stage and Routes of Administration, H1 2016 26
Number of Products by Molecule Types, H1 2016 28
Number of Products by Stage and Molecule Types, H1 2016 28
Companies
InSite Vision Incorporated
Kala Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Reata Pharmaceuticals, Inc.
Sylentis S.A.U.
Valeant Pharmaceuticals International, Inc.
- PRICE
-
$2000$6000